Loading…
Loading…
PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET.
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI's Duloxetine Delayed-Release Capsules are the generic version of the reference listed drug (RLD) Cymbalta®.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) CEO Nikhil Lalwani sold 5,400 shares of the firm's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $71.89, for a total transaction of $388,206.00. Following the completion of the transaction, the chief executive officer owned 333,689
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Talphera (NASDAQ: TLPH - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends. Analyst Recommendations This is a summary of current
Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026
Investors need to pay close attention to ANIP stock based on the movements in the options market lately.